Table 2

Baseline patient characteristics

Celecoxib

(n = 28,614)

nsNSAID

(n = 15,278)

Placebo

(n = 5,827)

Rofecoxib

(n = 1,329)

Total

(n = 51,048)

Age, years

Mean, SD

60.1 (13)

59.3 (13)

57.2 (14)

70.6 (9)

59.8 (13)

≥ 65 years, n (%)

11,404 (40)

5,667 (37)

1,901 (33)

1,115 (84)

20,087 (39)

≥ 75 years, n (%)

3,421 (12)

1,656 (11)

513 (9)

460 (35)

6,050 (12)

Female, n (%)

18,819 (66)

10,478 (69)

3,251 (56)

860 (65)

33,408 (65)

Indication

OA/RA, n (%)

23,324 (82)

13,911 (91)

3,074 (53)

1,329 (100)

41,638 (82)

Low-back pain, n (%)

1,743 (6)

850 (6)

1,042 (18)

0 (0)

3,635 (7)

Ankylosing spondylitis, n (%)

895 (3)

517 (3)

232 (4)

0 (0)

1,644 (3)

Alzheimer disease, n (%)

329 (1)

0 (0)

158 (3)

0 (0)

487 (1)

Oncology, n (%)

2,323 (8)

0 (0)

1,321 (23)

0 (0)

3,644 (7)

Duration, n (%)

≤ 12 weeks

15,597 (55)

8,322 (55)

3,871 (66)

1,245 (94)

29,035 (57)

> 12 and ≤ 26 weeks

7,878 (28)

4,271 (28)

675 (12)

84 (6)

12,908 (25)

> 26 and ≤ 52 weeks

2,307 (8)

1,958 (13)

90 (2)

0 (0)

4,355 (9)

≥ 52 weeks

2,832 (10)

727 (5)

1,191 (20)

0 (0)

4,750 (9)

Total patient-years of exposure

12,276.3

4,621.8

3,755.6

154.5

20,808.2

100 patient-years of exposure

122.8

46.2

37.6

1.6

208.1

100 Patient-years of exposure = total patient-years of exposure divided by 100. nsNSAID, nonselective nonsteroidal antiinflammatory drug; OA, osteoarthritis; RA, rheumatoid arthritis.

Moore et al. Arthritis Research & Therapy 2013 15:R6   doi:10.1186/ar4134